What to Do When Your GLP-1 Drug Is Out of Stock or Backordered

The supply situation as of 2025–2026

Between 2022 and 2024, semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) were on the FDA Drug Shortage List — meaning the FDA had formally determined that national supply was insufficient to meet demand.

The shortage designation had important regulatory consequences: while on the shortage list, compounding pharmacies could legally compound semaglutide and tirzepatide under §503A and §503B exemptions. This is why the compounded GLP-1 market grew rapidly during 2022–2024. For a clinical comparison of the two options, see compounded vs brand semaglutide.

In early 2025, both drugs were removed from the FDA shortage list after manufacturers certified adequate supply:

• Novo Nordisk stated Wegovy supply is adequate nationally (February 2025)
• Eli Lilly stated Zepbound supply is adequate nationally (March 2025)

However, national adequacy does not mean your pharmacy has your dose in stock. Supply is unevenly distributed. Specific doses (particularly higher doses like semaglutide 2.4 mg and tirzepatide 15 mg) are periodically backordered at individual pharmacies. Regional distribution disruptions occur regularly.

Step 1: Check other pharmacies before doing anything else

When a pharmacy says your prescription is out of stock, they mean their stock. Other pharmacies in your area may have it.

Practical steps:

1. Call or use the online check tools at major pharmacy chains: CVS, Walgreens, Walmart, Costco, and independent pharmacies
2. Ask specifically about your dose — availability varies by pen size
3. Ask if they have any incoming stock and when it arrives

Tools for checking:

• GoodRx's pharmacy comparison shows stock in some areas
• NovoCare's pharmacist locator (for Wegovy)
• LillyDirect's pharmacy search (for Zepbound)

Step 2: Consider the manufacturer direct programmes

NovoCare / Wegovy: Novo Nordisk's patient assistance programme operates via speciality pharmacies with somewhat more reliable supply than retail chains. If you are enrolled in NovoCare, contact them directly about supply. For enrolment steps, see the NovoCare Wegovy enrolment guide.

LillyDirect / Zepbound: Eli Lilly's direct programme also uses speciality pharmacy distribution. Similarly, contact LillyDirect directly if retail pharmacy stock is unavailable.

Step 3: Ask your prescriber about a temporary dose adjustment

If your dose is unavailable but a lower dose is in stock, ask your prescriber whether a temporary hold at the last available dose is appropriate.

What your prescriber may suggest:

• Hold at your current stabilised dose while awaiting restocking
• Temporarily reduce to the next lower dose if waiting would require skipping a scheduled injection
• Bridge with a different drug if clinically appropriate (rare, but possible)

Do not self-adjust doses without prescriber input. Skipping injections entirely for 2–4 weeks and then returning to your dose without re-titration can worsen side effects. For the full dose escalation schedule for Wegovy, see the Wegovy dose escalation guide.

Step 4: Understand what happens to your body if you miss doses

If you cannot get your prescription for 1–4 weeks:

• Weeks 1–2: Appetite begins returning, typically starting 7–10 days after the missed dose. Drug half-life for semaglutide is approximately 1 week; for tirzepatide approximately 5 days.
• Weeks 2–4: Hunger and food thoughts return to pre-treatment baseline in most patients. Cravings may return. Weight loss stalls and minor regain begins.
• More than 4 weeks: Meaningful weight regain is expected. Most of the initial regain is water weight and gut content, not fat, but fat regain follows.

A gap of 1–4 weeks is not a crisis. Missing doses is uncomfortable and slows progress but is not harmful to long-term outcomes if treatment resumes.

Step 5: Resuming after a gap

After missing 1–2 weeks: Resume at your usual dose. Most patients tolerate this without re-titration.

After missing 3–4 weeks: Many prescribers recommend dropping one dose step and re-escalating over 2–4 weeks to reduce re-initiation side effects.

After missing more than 4 weeks: Follow your prescriber's re-initiation protocol. Some recommend starting from the lowest titration dose; others recommend the step below your previous maintenance dose. There is no uniform standard.

What about switching to compounded versions during a shortage gap?

As of 2025, the FDA shortage-driven exemption for compounding has ended. §503A pharmacies can no longer legally compound semaglutide or tirzepatide for individual patients except under narrowly defined circumstances (documented allergy to a branded product component, for example).

If you are considering compounded versions:

• Ensure the compounding pharmacy is a §503A or §503B accredited pharmacy
• Understand you are using a drug that has not passed FDA manufacturing oversight
• Be aware that the regulatory situation continues to evolve

For current status on specific compounders, see our regulatory articles.

Managing the cost impact of supply disruptions

If a shortage at your usual pharmacy forces you to a higher-cost option, also review Wegovy without insurance for all available cost-reduction options:

• Specialty pharmacies through manufacturer programmes may have more consistent supply but require enrolment in advance
• Mail-order pharmacy (CVS Caremark, Express Scripts, OptumRx) often has more reliable supply for maintenance patients than walk-in retail
• GoodRx/Mark Cuban Cost Plus Drugs have negotiated prices on some GLP-1 drugs that may be lower than cash pay at major chains during supply crunches

Summary

GLP-1 drug shortages are less acute in 2025–2026 than during the 2022–2024 peak, but individual pharmacy stockouts remain common. The protocol when your prescription is unavailable: check other pharmacies first, contact manufacturer programmes, ask your prescriber about dose adjustment, and understand the physiological gap timeline. Missing 1–4 weeks is manageable with appropriate re-initiation. Proactive prescription management (not waiting until the last pen to refill) is the best long-term strategy.